First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ - Concepedia

Concepedia

Publication | Open Access

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

DOI Full Paper Access

273

Citations

17

References

2021

Year

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, D.-W. Kim, Adnan Nagrial, Mark Voskoboynik, Hyun Cheol Chung, Kathryn F. Mileham, Ulka N. Vaishampayan, Drew Rasco,

Annals of Oncology

Abstract

Vibostolimab plus pembrolizumab was well tolerated and demonstrated antitumor activity in patients with advanced solid tumors, including patients with advanced NSCLC.

References

	Year	Citations

Page 1